<DOC>
	<DOCNO>NCT01512108</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial evaluate safety efficacy daily administration liraglutide combination oral anti-diabetic drug ( OAD ) Japanese subject type 2 diabetes insufficiently control OAD monotherapy . All subject continue pre-trial OAD ( either glinide , metformin , alpha-glucosidase inhibitor thiazolidinedione ) trial unchanged type dose .</brief_summary>
	<brief_title>Safety Efficacy Liraglutide Combination With OAD Subjects With Type 2 Diabetes Insufficiently Controlled OAD Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Informed consent obtain trialrelated activity ( trialrelated activity procedure would perform normal management subject . ) Japanese subject type 2 diabetes monotherapy OAD ( either glinide , metformin , aglucosidase inhibitor thiazolidinedione ) within approve Japanese label addition diet exercise therapy . Total daily dose type drug remain unchanged least 8 week prior Visit 1 Type 2 diabetes mellitus ( clinically diagnose ) least 6 month HbA1c 7.010.0 % ( inclusive ) Body Mass Index ( BMI ) 40.0 kg/m^2 Outpatients plan educational hospitalisation purpose glycaemic control . However , hospitalisation training selfinjection Visit 2 longer one week allow Subjects able willing perform selfmonitoring plasma glucose ( SMPG ) Subjects know previous malignant tumor strongly suspect recurrence ( except basal cell skin cancer squamous cell skin cancer ) Calcitonin equal 160 pg/mL Personal history nonfamilial medullary thyroid carcinoma Family personal history multiple endocrine neoplasia type 2 ( MEN2 ) familial medullary thyroid carcinoma ( FMTC ) History chronic pancreatitis idiopathic acute pancreatitis Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge investigator hospitalisation diabetic ketoacidosis previous 6 month Treatment GLP1 receptor agonist dipeptidyl peptidase 4 ( DPP4 ) inhibitor within 12 week prior Visit 1 Having contraindication liraglutide OADs ( accord Japanese labelling )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>